This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schrump, D. S. Articles by Steinberg, S. M. Search for Related Content PubMed PubMed Citation Articles by Schrump, D. S. Articles by Steinberg, S. M.

Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura

Authors' Affiliations: ¹ Thoracic Oncology Section Surgery Branch, ² Medical Oncology Branch, ³ Biostatistics and Data Management Section, and ⁴ Center for Cancer Research, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland; and ⁵ Functional Genomics Facility, University of Chicago, Chicago, Illinois

Requests for reprints: David S. Schrump, Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 4-3942, 10 Center Drive, MSC 1201, Bethesda, MD 20892. Phone: 301-496-2128; E-mail: david_schrump{at}nih.gov.

Purpose: The DNA methylation paradox, manifested as derepression of cancer-testis antigens, and silencing of tumor suppressors during malignant transformation, provides the rationale for the utilization of chromatin remodeling agents for cancer therapy. A phase I trial was done to examine pharmacokinetics, toxicities, and gene expression mediated by 5-aza-2'-deoxycytidine (DAC) in patients with thoracic malignancies.

Experimental Design: Thirty-five patients with cancers refractory to standard therapy received continuous 72-hour DAC infusions using a phase I dose-escalation schema. Each full course of therapy consisted of two identical 35-day cycles. Plasma DAC levels were evaluated by liquid chromatography-mass spectrometry techniques. Quantitative reverse transcription-PCR, methylation-specific PCR, and immunohistochemical techniques were used to evaluate NY-ESO-1, MAGE-3, and p16 expression in tumor biopsies. Long oligonucleotide arrays were used to evaluate gene expression profiles in laser-captured tumor cells before and after DAC exposure.

Results: Thirty-five patients were evaluable for toxicities; 25 were evaluable for treatment response. Myelosuppression constituted dose-limiting toxicity. The maximum tolerated dose of DAC was 60 to 75 mg/m² depending on the number of prior cytotoxic chemotherapy regimens. No objective responses were observed. Plasma DAC concentrations approximated thresholds for gene induction in cultured cancer cells. Target gene induction was observed in 36% of patients. Posttreatment antibodies to NY-ESO-1 were detected in three patients exhibiting NY-ESO-1 induction in their tumor tissues. Complex, heterogeneous gene expression profiles were observed in pretreatment and posttreatment tissues.

Conclusion: Prolonged DAC infusions can modulate gene expression in primary thoracic malignancies. These findings support further evaluation of DNA-demethylating agents alone or in combination with other regimens targeting induced gene products for the treatment of these neoplasms.

This article has been cited by other articles:

				A. Woloszynska-Read, P. Mhawech-Fauceglia, J. Yu, K. Odunsi, and A. R. Karpf Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer Clin. Cancer Res., June 1, 2008; 14(11): 3283 - 3290. [Abstract] [Full Text] [PDF]

				D. S. Schrump, M. R. Fischette, D. M. Nguyen, M. Zhao, X. Li, T. F. Kunst, A. Hancox, J. A. Hong, G. A. Chen, E. Kruchin, et al. Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin Clin. Cancer Res., January 1, 2008; 14(1): 188 - 198. [Abstract] [Full Text] [PDF]

				L. Fini, M. Selgrad, V. Fogliano, G. Graziani, M. Romano, E. Hotchkiss, Y. A. Daoud, E. B. De Vol, C. R. Boland, and L. Ricciardiello Annurca Apple Polyphenols Have Potent Demethylating Activity and Can Reactivate Silenced Tumor Suppressor Genes in Colorectal Cancer Cells J. Nutr., December 1, 2007; 137(12): 2622 - 2628. [Abstract] [Full Text] [PDF]

				E. R. Plimack, D. J. Stewart, and J.-P. J. Issa Combining Epigenetic and Cytotoxic Therapy in the Treatment of Solid Tumors J. Clin. Oncol., October 10, 2007; 25(29): 4519 - 4521. [Full Text] [PDF]

				E. Fonsatti, H. J.M. Nicolay, L. Sigalotti, L. Calabro, L. Pezzani, F. Colizzi, M. Altomonte, M. Guidoboni, F. M. Marincola, and M. Maio Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2'-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications Clin. Cancer Res., June 1, 2007; 13(11): 3333 - 3338. [Abstract] [Full Text] [PDF]

				Z. S. Guo, N. P. Restifo, and D. S. Schrump 5-AZA-2'-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story Cancer Res., March 15, 2007; 67(6): 2901 - 2901. [Full Text] [PDF]